Calcium gluconate, 100 mg/ml 5 ml 10 pcs

.

Indications

– Diseases accompanied by hypocalcemia, increased permeability of cell membranes, impaired nerve impulse conduction in muscle tissue.

– Hypoparathyroidism (latent tetany, osteoporosis), disorders of vitamin D metabolism: rickets (spasmophilia, osteomalacia), hyperphosphatemia in patients with chronic renal insufficiency.

– Increased need for calcium ions (pregnancy, breastfeeding, period of intense growth of the body), insufficient content of calcium ions in food, disorders of calcium metabolism (in the postmenopausal period).

– Increased excretion of calcium ions (prolonged bed rest, chronic diarrhea, secondary hypocalcemia on prolonged use of diuretics and antiepileptic drugs, glucocorticosteroids).

– Bleeding of various etiologies.

– Allergic diseases (serum sickness, urticaria, febrile syndrome, pruritus, pruritic dermatosis(s), reactions to the administration of drugs and food intake, angioedema); bronchial asthma, dystrophic alimentary edema, pulmonary tuberculosis, rickets, osteomalacia, lead colic; eclampsia.

– Hyperkalemic form of paroxysmal myoplegia.

Composition

Per 1 ml:

Active ingredient: calcium gluconate – 100.0 mg.

Auxiliary substances:

succinic acid – 5.0 mg, sodium hydroxide solution 1 M – to pH 6.0-7.5, water for injection – to 1.0 ml.

How to take, the dosage

Serum calcium concentrations should be monitored during treatment.

The drug is injected deeply intramuscularly, or intravenously slowly (over 2-3 minutes), or by drip to avoid the possibility of local irritation or necrosis if the drug enters the perivascular tissues.

Because of the risk of local irritation, intramuscular injections should only be given if intravenous injection is not possible.

Intramuscular injections should be made deep enough into the muscle, preferably in the gluteal area.

Adults: deeply intramuscularly, slowly intravenously (within 2-3 minutes) or by drip 5-10 ml of 10% solution daily, every other day or every 2 days (depending on the nature of the disease and clinical condition of the patient). Subsequent doses are determined in accordance with the concentration of calcium in blood serum.

In children under 18 years of age: the dose and method of administration depend on the degree of hypocalcemia, the nature and severity of symptoms.

In children, depending on their age, the drug is administered in the following doses: up to 6 months, 0.1-1 ml; 7-12 months, 1-1.5 ml; 1-3 years -1.5-2 ml; 4-6 years – 2-2.5 ml; 7-14 years – 3-5 ml; over 14 years – doses as for adults. The drug is administered every 2-3 days.

In children, intramuscular administration of the drug is not recommended because of the possible development of necrosis.

Only slow intravenous injection or intravenous infusion after dilution is recommended to achieve sufficiently low rates of administration and to avoid the possibility of local irritation or necrosis if the drug accidentally enters the perivascular tissues.

For intravenous infusion the drug is diluted 1:10 to a concentration of 10 mg/ml with the following infusion solutions: 0.9% sodium chloride solution or 5% glucose solution. The rate of intravenous injection should not exceed 50 mg of calcium gluconate per minute.

The solution is warmed to body temperature before administration. Syringe for calcium gluconate injection should not contain residual ethanol (in order to avoid precipitation of calcium gluconate).During intramuscular and intravenous administration nausea, vomiting, diarrhea, bradycardia may be observed. When administered intravenously, burning in the mouth, a feeling of heat may be observed; when administered rapidly intravenously, a decrease in blood pressure, arrhythmia, fainting, cardiac arrest may occur.

In intramuscular injection may cause necrosis at the site of injection.

Interaction

Pharmaceutically incompatible with ethanol, carbonates, salicylates, sulfates (forms insoluble or hardly soluble calcium salts). Forms insoluble complexes with tetracycline antibiotics (reduces antibacterial effect).

Limits the effect of “slow” calcium channel blockers (intravenous administration of calcium gluconate before or after verapamil reduces its hypotensive effect).

Concomitant use with quinidine may slow intraventricular conduction and increase quinidine toxicity.

Parenteral use of calcium gluconate is not recommended during treatment with cardiac glycosides (increased cardiotoxic effect of cardiac glycosides is possible).

In combination with thiazide diuretics may increase hypercalcemia. Reduces the effect of calcitonin in hypercalcemia. Reduces the bioavailability of phenytoin.

Special Instructions

The drug is heated to body temperature before injection.

Intravenous administration may cause a sensation of fever throughout the body, which passes quickly.

Serum calcium concentrations should be monitored closely during treatment.

Because of the risk of local irritation, intramuscular injections should only be given if intravenous injection is not possible.

Intramuscular injections should be performed deep into the muscle, preferably in the gluteal area. For obese patients, a longer needle should be selected to inject safely into the muscle and not into the fatty tissue. If repeated injections are necessary, the injection site should be changed each time.

In intravenous administration of calcium gluconate, in exceptional cases, patients receiving cardiac glycosides need cardiac monitoring and conditions for urgent treatment of cardiac complications, such as severe arrhythmias, should be provided.

Renal dysfunction may be associated with hypercalcemia and secondary hyperparathyroidism. Therefore, in patients with impaired renal function parenteral administration of calcium should be administered only after careful determination of indications, and the calcium-phosphate balance should be monitored.

In patients with mild hypercalciuria, decreased glomerular filtration or with a history of nephrourolithiasis, treatment should be performed under control of urinary calcium ion concentration.

A lot of drinking is recommended to reduce the risk of nephrourolithiasis.

Contraindications

Overdose

Pregnancy use